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Abstract
This review focuses on recent human 18F-FDG PET studies in Parkinson’s disease. First, 
an overview is given of the current analytic approaches to metabolic brain imaging 
data. Next, we discuss how 18F-FDG PET studies have advanced understanding of 
the relation between distinct brain regions and associated symptoms in Parkinson’s 
disease, including cognitive decline. In addition, the value of 18F-FDG PET studies in 
differential diagnosis, identifying prodromal patients and the evaluation of treatment 
effects are reviewed. Finally, anticipated developments in the field are addressed.
Introduction
Parkinson’s disease (PD) is a common neurodegenerative disorder and its prevalence 
is likely to increase in the next decades. Although the exact cause is unknown, the 
disease is associated with a gradual accumulation of the misfolded synaptic protein 
α-synuclein in the nervous system. The pathology is suggested to start in the gut 
(or olfactory bulb) and spreads via the dorsal motor nucleus of the vagal nerve to 
the brainstem (Klingelhoefer, Reichmann, 2015). Subsequently, the pathologic 
process reaches the substantia nigra pars compacta in the mesencephalon, where 
the dopaminergic neurons reside. These neurons give important dopaminergic 
input to the striatum. Degeneration results in a cascade of dysfunction in several 
neural networks connecting the basal ganglia, thalamus and cortical motor regions 
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(Weingarten et al., 2015). This process is associated with the typical motor features 
of the disease: slowness of movement (bradykinesia), muscle stiffness (rigidity), and 
sometimes rest tremor; together referred to as parkinsonism. 
 PD is a clinical diagnosis, and can be straightforward in a patient with 
parkinsonism who has an excellent and sustained levodopa response (Postuma et 
al., 2015). However, parkinsonism is also an early sign of other neurodegenerative 
disorders such as multiple system atrophy (MSA), progressive supranuclear palsy 
(PSP) and corticobasal degeneration (CBD). Differentiating between these disorders 
at early disease stages can be challenging, and clinicopathologic studies show that 
the clinical diagnosis of PD is often incorrect in the early stages (Adler et al., 2014). 
This is problematic, because accurate, early diagnosis is important for patient 
management, prognosis, and patient selection for clinical trials. The diagnosis of 
neurodegenerative parkinsonism can be supported by presynaptic dopaminergic 
radiotracer studies. However, at an individual level, presynaptic dopaminergic tracer 
studies cannot differentiate between PD, MSA, PSP, or CBD (Ko, Lee & Eidelberg, 
2016). 
 Pathology in PD is widespread, involving neurotransmitters other than 
dopamine and distributed brain regions participating in neural networks. In addition 
to parkinsonism, PD patients experience multiple nonmotor symptoms including 
cognitive, mood, sleep, olfactory, and autonomic disorders. Some of these nonmotor 
symptoms can precede motor features by many years. Identifying patients in such 
a prodromal phase will be important for enrolling patients in neuroprotective trials 
(Berg et al., 2015). The strongest prodromal marker of PD is idiopathic Rapid Eye 
Movement sleep behavior disorder (RBD), a parasomnia that can be diagnosed with 
a polysomnography. Patients with RBD fail to suppress muscle tone during the 
REM sleep stage, leading to dream enactment. Longitudinal studies have shown that 
more than 80% of patients initially diagnosed with idiopathic RBD developed PD, 
dementia with Lewy bodies (DLB), or incidentally MSA in the following decades 
(Iranzo et al., 2014). 
 At later disease stages, dementia is a common problem in PD, often preceded 
by mild cognitive impairment (MCI). Patients with DLB present with cognitive 
impairment and parkinsonism (Postuma et al., 2015). Identifying patients at risk of 
developing cognitive impairment or dementia is important for patient management, 
and for clinical trials targeting early interventions to prevent dementia.
 Neuro-imaging studies have provided considerable insight in the 
neurobiological basis of PD and its different clinical profiles (Weingarten et al., 
2015). Imaging of brain glucose metabolism is an important contributor to the 
field. Glucose metabolism can be measured accurately and reliably with 18F-FDG 
PET. This technique is increasingly available for routine clinical practice. The 























step of the cellular glycolytic pathway (Alavi, Reivich, 2002). Cerebral glucose 
metabolism is closely associated with local neural integrity and density. 18F-FDG 
uptake increases with synaptic activity and decreases with neural dysfunction in a 
pattern-like manner, following the neuronal systems that are affected. 18F-FDG PET 
studies are especially relevant in PD and other neurodegenerative diseases, where 
neuronal dysfunction precedes structural changes not detected by anatomic brain 
imaging. The current review focuses on recent human 18F-FDG PET studies in PD. 
Both glucose metabolism and cerebral blood flow are coupled to regional neuronal 
activity. Therefore, where necessary, we also review a few radioactively labeled water 
studies (e.g., H2
15O PET) or perfusion SPECT (99mTc-labeled ethylcysteinate dimer 
SPECT) studies. 
Analysis of 18F-FDG PET Images 
The analysis of 18F-FDG PET images starts with the registration of images to 
standard anatomical space, to allow voxel-based comparisons between subjects. 
Next, inter-individual variability is reduced, usually by dividing each voxel value by 
the global mean or another reference value. After anatomical registration and ratio-
normalization, a common and straightforward approach to the analysis of 18F-FDG 
PET images is the application of univariate models in the software package statistical 
parametric mapping (SPM; http://www.fil.ion.ucl.ac.uk/spm/). In such studies, 
regions of altered relative 18F-FDG uptake in patients compared with controls are 
identified, or correlations between 18F-FDG uptake in certain regions and clinical 
metrics are determined. A key characteristic of univariate approaches is that every 
region or voxel is treated separately. 
 However, it is increasingly recognized that PD is characterized by stereotyped 
connectivity changes, and that studying networks, rather than separate regions, 
provides more insight in pathophysiologic mechanisms underlying PD. Covariance 
analysis techniques are considered appropriate methods to explore network activity. A 
well-investigated approach is the Scaled Subprofile Model with Principal Component 
Analysis (SSM PCA). SSM PCA identifies disease-specific patterns of altered glucose 
metabolism in combined samples of resting-state scans of patients and controls 
(Spetsieris, Eidelberg, 2011). Briefly, between-subject and between-region variability 
is removed from log-transformed imaging data. Next, the covariance is calculated 
between all voxels, and the data are reduced with Principal Component Analysis 
(PCA). The components that best discriminate between controls and patients are 
identified as the relevant disease-related pattern. An important advantage of this 
approach is that once a pattern has been identified, the degree of its expression 
can be quantified in any 18F-FDG PET scan. This expression score is reflected by 
a single numeric value that can be used to investigate relationships with clinical or 
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physiologic metrics or to make predictions.
 For multivariate analysis of 18F-FDG PET images with multiple conditions 
(i.e., multiple scans per subject), ordinal trends canonical variates analysis (OrT/
CVA) can be applied. This algorithm identifies relevant spatial covariance patterns 
within subjects, for which subject expression increases or decreases in most 
individuals across scan conditions, whereas the relationships between brain regions 
remain constant (Habeck et al., 2005). 
Metabolic Profile of PD
A disease-specific pattern for PD was first identified by Eidelberg et al. (Eidelberg 
et al., 1994, Ma et al., 2007) and has been validated in multiple independent 
populations (Wu et al., 2013, Niethammer, Eidelberg, 2012, Teune et al., 2013, 
Teune et al., 2014). The PD-related pattern (PDRP) is consistently characterized 
by relatively increased metabolism in the globus pallidus and putamen, thalamus, 
cerebellum, pons, and sensorimotor cortex and relative decreases in the lateral frontal 
and parietooccipital areas (Figure 1A), similar to results from univariate group 
contrasts (Teune et al., 2010). The clinical and pathophysiologic correlates of the 
PDRP have been investigated extensively (Niethammer, Eidelberg, 2012). PDRP 
expression correlates positively with akinetic-rigid motor symptoms and disease 
duration and negatively with uptake of presynaptic dopaminergic markers in the 
posterior striatum (Holtbernd et al., 2015). 
 Interestingly, the PDRP is not related to tremor, probably reflecting the 
distinct pathophysiologic origins of bradykinesia/rigidity and tremor. A separate 
tremor-related pattern (PDTP) was identified with OrT/CVA applied to 18F-FDG 
PET data of nine tremor-dominant PD patients before and after thalamic deep brain 
stimulation (DBS) (Mure et al., 2011). The PDTP was characterized primarily by 
increases in the cerebellum and primary motor cortex. PDTP expression scores were 
correlated to tremor but not to bradykinesia/rigidity. 
 It has also been shown that motor networks described in normal condition 
are disturbed in PD (Ko et al., 2013). Derived from cerebral blood flow measurements 
during a motor task and at rest, a normal movement-related activation pattern was 
identified with OrT/CVA, of which the activation was subsequently compared with 
that in rest. This motor pattern comprised the sensorimotor, premotor, and inferior 
parietal cortex and the cerebellar vermis, being activated in both controls and PD 
patients during task performance. However, whereas the motor pattern was not 
activated at rest in controls, PD patients strikingly failed to repress the motor pattern 
at rest, irrespective of tremor. Expression of this normal motor pattern at rest was 
present at the early clinical stages of PD and increased with disease progression, 























 Another well-defined network that is disturbed in PD is the default mode 
network (DMN). The DMN is identified with functional MRI and describes normal 
regional brain activity at rest, in the absence of focused cognitive activity. A resting-
state network resembling the DMN has also been identified in 18F-FDG PET data 
with SSM (Spetsieris et al., 2015). In controls and early PD patients, expression of 
this PET-derived DMN was lower during a task than the rest condition. However, 
in advanced PD, this physiologic task-related deactivation of the DMN was lost. 
Moreover, with advancing disease, resting-state brain organization moved away from 
the DMN and was increasingly dominated by a pathologic network: the PDRP. 
PD and Cognitive Impairment 
Distinct PD subtypes, such as postural instability gait disorder and PD patients 
with RBD, are associated with a higher risk of developing dementia. In contrast, 
patients with a tremor-dominant phenotype rarely develop dementia. Zhang et al. 
found additional hypometabolism in the caudate nucleus and inferior parietal lobule 
in patients with postural instability gait disorder compared with tremor-dominant 
patients (Zhang et al., 2016). Decreased metabolism in parietal-occipital regions was 
found in PD patients with RBD compared with PD patients without RBD (Arnaldi 
et al., 2016). Compared with patients with PD or PD dementia, DLB patients show 
more pronounced hypometabolism of the visual association cortices (Mak et al., 
2014). Occipital hypometabolism is associated with visual hallucinations, which are 
common in DLB but may also occur in PD. PD patients with visual hallucinations 
indeed also show occipital hypometabolism and have a higher risk of developing 
dementia than patients without visual hallucinations (Gasca-Salas et al., 2016). 
 Both cross-sectional (Garcia-Garcia et al., 2012, Pappata et al., 2011) and 
longitudinal (Bohnen et al., 2011, Tard et al., 2015, Fujishiro et al., 2013, Shoji et 
al., 2014) 18F-FDG PET studies using univariate designs have shown that progressive 
cortical hypometabolism, especially of parietal and occipital regions, marks the 
transition from normal cognition to dementia in PD and DLB. In addition, a study 
combining 18F-FDG PET with structural imaging concluded that hypometabolism 
predates atrophy in these brain regions (Gonzalez-Redondo et al., 2014). Thus, 
hypometabolism and atrophy are consecutive stages of the same process, which is 
progressive in nature and is associated with the development of cognitive decline. 
 Network studies (SSM PCA) have revealed a consistent metabolic pattern 
associated with cognitive decline in nondemented PD patients (Huang et al., 2007, 
Meles et al., 2015). This PD cognition-related pattern (PDCP) is characterized by 
hypometabolism in frontal and parietal association regions, and hypermetabolism 
in the cerebellar dentate nuclei (Figure 1B). PDCP expression was correlated to 
executive and memory performance but not to motor scores. Furthermore, PDCP 
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expression was significantly higher in PD patients with mild cognitive impairment 
than in their cognitively unimpaired counterparts. 
 Although cognitive dysfunction may be influenced by many 
neurotransmitter systems, degeneration of cholinergic and dopaminergic projections 
are thought to be the most important (Gratwicke, Jahanshahi & Foltynie, 2015). 
The dopaminergic system not only projects to motor pathways, but also to the 
lateral prefrontal cortices via the caudate. This frontostriatal system is intimately 
connected with the posterior parietal cortex and is related to executive and memory 
functioning. Associations found between PDCP topography (a frontoparietal 
network), decreased uptake of presynaptic dopaminergic markers in the caudate 
nucleus, and executive and memory dysfunction imply that the PDCP is caused 
by disintegration of fronto-striatal circuits (Holtbernd et al., 2015, Niethammer et 
al., 2013). The cholinergic system originates in the nucleus basalis of Meynert in 
the basal forebrain and the pedunculopontine nucleus (PPN) in the brain stem. 
DLB and PDD are associated with severe cholinergic deafferentiation of the 
neocortex, especially in parietooccipital regions. This is congruent with 18F-FDG 
PET findings of posterior hypometabolism in dementia (Klein et al., 2010). 
Figure 1. Disease-specific patterns in parkinsonian disorders identified with SSM PCA.
Visualization of PDRP (A) (Teune et al., 2014), PDCP (B) (Meles et al., 2015), MSA-related 
pattern (MSARP) (C) (Teune et al., 2013), and PSP-related pattern (PSPRP) (D) (Teune et al., 
2013). All patterns are displayed as z-maps, thresholded at |z > 1| (as indicated by the color bar), 

























SPM studies contrasting healthy controls with PSP, MSA and CBD cases have found 
consistent metabolic patterns in each condition, which are distinct from the PD 
metabolic profile (Teune et al., 2010). MSA is characterized by hypometabolism 
in the putamen and cerebellum; PSP by hypometabolism in the prefrontal cortex, 
frontal eye fields, caudate nuclei, medial thalamus and upper brainstem; and CBD 
by hypometabolism of the cortex and basal ganglia of one hemisphere and the 
contralateral cerebellum. In routine clinical practice, the 18F-FDG PET scan of a 
patient can be assessed visually with reference to these typical vignettes (Figure 2). 
Hellwig et al. analyzed 18F-FDG PET scans of parkinsonian patients with an unclear 
diagnosis by visual assessment combined with individual voxel based statistical maps 
(3-dimensional stereotactic surface projection technique). Consensus interpretation 
of the 18F-FDG PET image was compared with the clinical diagnosis after 1-y 
follow-up. Sensitivity and specificity were, respectively, 86% and 91% for PD versus 
not-PD, 77% and 97% for MSA, 74 and 95% for PSP, and 75% and 97% for 
CBD. This study underscores the value of 18F-FDG PET for differential diagnosis 
of neurodegenerative parkinsonism in a clinical setting (Hellwig et al., 2012). An 
important restriction of this approach is that an expert is needed for correct visual 
assessment, and that the 3-dimensional stereotactic surface projection technique 
method does not cover the striatum. 
 With SSM PCA, disease-specific patterns have been identified not only 
for PD (Figure 1A), but also for MSA (Figure 1C), PSP (Figure 1D) and CBD 
(Niethammer, Eidelberg, 2012, Teune et al., 2013, Niethammer et al., 2014). 
These patterns mirror findings of univariate studies but can be especially useful in 
differential diagnosis, because expression of these patterns can be quantified on a 
prospective case basis (Figure 3). When expression scores for each of these patterns are 
calculated in individual patients, there can be some overlap between disease groups 
(Ko, Lee & Eidelberg, 2016). Differential diagnosis is therefore better achieved by 
combining several pattern scores in a statistical model. A logistic 2-step model which 
first differentiates between PD and not-PD and subsequently between MSA and PSP, 
was tested in 2 cohorts of patients with parkinsonism and an uncertain diagnosis 
at the time of imaging (n =167 (Tang et al., 2010b) and n = 129 (Tripathi et al., 
2015)). After a follow-up of 2 years by a movement disorders specialist masked for 
the 18F-FDG PET, clinical diagnosis accorded well with the pattern diagnosis in both 
studies, with similarly high sensitivity and specificity. The sensitivity and specificity 
were, respectively, 83% and 94% for PD versus not-PD, 79% and 90% for MSA, 
and 100% and 94% for PSP. The diagnostic accuracy was similarly high when the 
model was applied to a subgroup of patients with a very short symptom duration (<2 
y) (Tripathi et al., 2015). 
54
 Other classification algorithms have also been tested. Mudali et al. combined 
SSM PCA features with several classifiers, comparing multiple groups in the same 
model. Performance of nearest neighbors and linear support vector machine gave the 
best classification of controls, PD, PSP and MSA subjects, although performance 
was not as high as in the studies discussed above (Mudali et al., 2015). Garraux 
et al. applied relevance vector machine to the classification of 120 patients with 
parkinsonism, which yielded high performance for PD versus not-PD (sensitivity, 
93%; specificity, 83%), but classification of MSA and PSP was poor (Garraux et al., 
2013). 
Figure 2. Typical examples of transversal 18F-FDG PET brain images of individual patients 
with neurodegenerative parkinsonism. (Reprinted from Booij, J., Teune, L.K., Verberne, H.J., 
The role of molecular imaging in the differential diagnosis of parkinsonism, Q J Nucl Med Mol 























Predicting PD Onset in Idiopathic RBD
Because idiopathic RBD is the strongest currently known predictor of PD, a growing 
number of studies have tried to identify reliable neuroimaging markers to predict 
the onset of parkinsonism in these prodromal individuals (Heller et al., 2016). Two 
studies demonstrated that idiopathic RBD patients significantly express the PDRP 
(Wu et al., 2014, Holtbernd et al., 2014). This finding was confirmed by our group 
(Meles et al., 2017b). Holtbernd et al. included long-term clinical follow-up data 
of 17 idiopathic RBD patients, which revealed that phenoconversion to PD/DLB 
was more likely in individuals with high PDRP expression at baseline. In contrast, 
3 idiopathic RBD patients who developed MSA 2-4 years later did not express the 
PDRP at baseline. A logistic regression model based on PDRP expression and age 
at baseline could accurately predict phenoconversion to PD/DLB (Holtbernd et al., 
2014). These findings indicate that network expression has potential as a marker for 
phenoconversion and may have additional value in predicting which phenotype a 
patient with idiopathic RBD will develop.
Figure 3. Preliminary data from the Glucose Imaging in Parkinsonian Syndromes (GLIMPS) 
Project. Individual PDRP and MSARP expression values are displayed for patients with a 
clinical diagnosis of probable PD and probable MSA (of the parkinsonian subtype, MSA-P). 
MSARP = MSA-related pattern.
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Treatment Effects 
Because the PDRP is expressed in early and prodromal disease, increases with 
disease severity and progression, and is useful in differential diagnosis, PDRP 
expression could be considered as a biomarker for PD in clinical trials. In that case, 
PDRP expression should also be modulated by effective therapies. Indeed, PDRP 
expression decreased after subthalamotomy, DBS of the subthalamic nucleus (STN), 
and levodopa treatment (Figure 4). Moreover, clinical improvement after therapy 
correlated to the degree of PDRP modulation (Niethammer, Eidelberg, 2012). The 
effect of levodopa on brain metabolism and blood flow, especially from a network 
perspective, has been reviewed recently (Ko, Lerner & Eidelberg, 2015). 
 The effect of treatment on other PD networks has also been evaluated. The 
PDTP was modulated by DBS of the ventral intermediate (Vim) thalamic nucleus, 
whereas the PDRP was not. Although STN DBS reduced activity of both PDTP and 
PDRP, PDTP was better modulated by Vim DBS than by STN DBS (Mure et al., 
2011). 
 The effect of levodopa on PDCP expression is not as straightforward as 
the effect on PDRP expression. Interestingly, only certain patients show a decrease 
in PDCP expression after levodopa therapy. These patients, so-called cognitive 
responders, showed improved executive functioning after levodopa administration. 
Cognitive responders are usually patients with more advanced cognitive impairment, 
signified by more extensive caudate dopamine depletion and a higher PDCP score at 
baseline (Ko, Lerner & Eidelberg, 2015). 
 Evaluation of therapies for PD has been challenging due to clinical 
improvement in patients receiving sham/placebo treatments. The underlying 
network effects of this sham response were studied with 18F-FDG PET and OrT/
CVA in a cohort of PD patients who participated in a randomized controlled trial 
of a gene therapy (Ko et al., 2014). A spatial covariance pattern associated with 
motor improvement 6 months after sham surgery was identified, characterized by 
hyperactivity of the cerebellum and paralimbic structures. This sham-related pattern 
was expressed in sham responders under the mask, but declined significantly after 
unmasking. Expression was absent in patients not responding clinically to sham 
surgery and in active therapy responders. Expression of the sham-related pattern 
at baseline (i.e., before surgery) could predict motor responses 6 months after 
sham surgery and may thus reflect a proneness to positive expectancy. The authors 
























Figure 4. Modulation of PDRP expression in response to treatment (mean ± SE). Shaded bars 
indicate the change in PDRP expression after stereotactic surgery targeting STN: microlesion 
(n=6), subthalamotomy (n=6) and DBS (n=18). Solid bar indicates changes in PDRP 
expression in response to levodopa (LD) administration (n = 18). Changes were significant after 
subthalamotomy, STN DBS, and levodopa treatment but not microlesion (**P<0.01, *** P 
<0.001 for the comparison of changes in PDRP expression with each intervention with those 
observed during test-retest evaluation, RMANOVA). Reprinted from Niethammer M, Eidelberg 
D. Metabolic brain networks in translational neurology: concepts and applications. Ann Neurol. 
72:635-647, Copyright 2012, with permission from John Wiley and Sons).
Future Perspectives 
Network analysis of 18F-FDG PET data may provide appropriate biomarkers for PD, 
which will be important when neuroprotective compounds may be studied in clinical 
trials. Especially the PDRP has been thoroughly investigated, and initial studies in 
prodromal PD are promising. The PDCP requires further validation, especially in 
longitudinal studies. 
 Recent advances of combined PET/MR imaging may allow better anatomic 
registration of 18F-FDG images and investigation of precise structural-functional 
correlates in PD. Combining multiple imaging features in machine learning 
approaches may improve classification of individual patients. Quantification tools 
are needed that can be applied easily and reliably for purposes of differential diagnosis 
across centers. In this context, the influence of different imaging protocols on image 
classification needs to be investigated. 
 These goals may best be achieved by a combined effort of multiple neurology 
and nuclear medicine centers. A first step in this direction has been made with the 
Glucose Imaging in Parkinsonian Syndromes (GLIMPS) project by the Groningen 
group (http://glimpsproject.com/). 
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